Antalgenics, S.L.

Based in Spain, Antalgenics, S. L. focuses on the innovative design and development of active molecules for biomedical and dermocosmetic applications, enhancing skin health through specialized products. Founded in 2015, Antalgenics, S.

L. specializes in creating innovative active molecules for biomedical and dermocosmetic applications. The company is headquartered in Spain. The CEO, Philipp Tsolakis, leads the firm which operates without any known subsidiaries.

Antalgenics has successfully raised funding through various rounds, focusing on advancing its R&D initiatives. Antalgenics specializes in the design and development of innovative active molecules intended for biomedical and dermocosmetic applications. The company’s core offerings include proprietary products such as Calmapsin® and Capsisilence®, which are aimed at addressing sensory neurobiology and enhancing skin health. These products are developed through a rigorous R&D program that focuses on translating scientific findings into practical solutions for improving quality of life.

Antalgenics targets a diverse customer base that includes pharmaceutical companies, healthcare providers, and cosmetic manufacturers, primarily in Europe and North America. Their focus on licensing out leads that have progressed to Phase II/III clinical trials further extends their reach in the market as they collaborate with third parties for tailored R&D projects. In 2023, Antalgenics generated a revenue of USD 147,810. 70, with an EBITDA of USD -199,334.

60. The company generates revenue through multiple channels, primarily by licensing its developed products and technologies to external partners in the pharmaceutical and cosmetic sectors. The pricing structure for its flagship products and services aligns with industry standards for biotechnological products, reflecting the complexity of the research and development involved. Revenue is also supplemented through partnerships with clients who seek to incorporate Antalgenics' innovations into their own product lines, facilitating a steady income stream from collaborative ventures.